WO1999050433A1 - Methode de production de lysosphingolipides - Google Patents
Methode de production de lysosphingolipides Download PDFInfo
- Publication number
- WO1999050433A1 WO1999050433A1 PCT/JP1999/001610 JP9901610W WO9950433A1 WO 1999050433 A1 WO1999050433 A1 WO 1999050433A1 JP 9901610 W JP9901610 W JP 9901610W WO 9950433 A1 WO9950433 A1 WO 9950433A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- producing
- ether
- lysosphingolipid
- organic solvent
- reaction
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 39
- 239000003960 organic solvent Substances 0.000 claims abstract description 46
- 239000004094 surface-active agent Substances 0.000 claims abstract description 34
- 150000003408 sphingolipids Chemical class 0.000 claims abstract description 33
- 239000012071 phase Substances 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 21
- 102000004190 Enzymes Human genes 0.000 claims abstract description 21
- 239000008346 aqueous phase Substances 0.000 claims abstract description 19
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 15
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 14
- 229930195729 fatty acid Natural products 0.000 claims abstract description 14
- 239000000194 fatty acid Substances 0.000 claims abstract description 14
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims abstract description 11
- 238000006911 enzymatic reaction Methods 0.000 claims abstract description 8
- 238000006243 chemical reaction Methods 0.000 claims description 47
- 238000004519 manufacturing process Methods 0.000 claims description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 23
- -1 polyoxyethylene Polymers 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 12
- 150000002430 hydrocarbons Chemical class 0.000 claims description 12
- 229930195733 hydrocarbon Natural products 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 150000001298 alcohols Chemical class 0.000 claims description 6
- 150000005215 alkyl ethers Chemical class 0.000 claims description 5
- 150000002170 ethers Chemical class 0.000 claims description 5
- 239000004215 Carbon black (E152) Substances 0.000 claims description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 3
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 125000001033 ether group Chemical group 0.000 claims description 2
- 125000005586 carbonic acid group Chemical group 0.000 claims 1
- 125000002345 steroid group Chemical group 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 239000011541 reaction mixture Substances 0.000 abstract 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 33
- OIPPWFOQEKKFEE-UHFFFAOYSA-N orcinol Chemical compound CC1=CC(O)=CC(O)=C1 OIPPWFOQEKKFEE-UHFFFAOYSA-N 0.000 description 20
- YXHRQQJFKOHLAP-FVCKGWAHSA-M sodium;2-[[(4r)-4-[(3r,5r,8r,9s,10s,12s,13r,14s,17r)-3,12-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]ethanesulfonate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 YXHRQQJFKOHLAP-FVCKGWAHSA-M 0.000 description 18
- 229940045946 sodium taurodeoxycholate Drugs 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 241000589774 Pseudomonas sp. Species 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 14
- 239000008351 acetate buffer Substances 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 13
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 13
- 229940106189 ceramide Drugs 0.000 description 13
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 13
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 239000013504 Triton X-100 Substances 0.000 description 12
- 229920004890 Triton X-100 Polymers 0.000 description 12
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 11
- 238000003384 imaging method Methods 0.000 description 10
- 108010078209 sphingolipid ceramide N-deacylase Proteins 0.000 description 10
- 108010032220 cyclomaltodextrinase Proteins 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 241000186361 Actinobacteria <class> Species 0.000 description 6
- 241000589516 Pseudomonas Species 0.000 description 6
- 150000002339 glycosphingolipids Chemical class 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 6
- 108090000751 Ceramidases Proteins 0.000 description 5
- 102000004201 Ceramidases Human genes 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
- 239000006227 byproduct Substances 0.000 description 4
- RWGFKTVRMDUZSP-UHFFFAOYSA-N cumene Chemical compound CC(C)C1=CC=CC=C1 RWGFKTVRMDUZSP-UHFFFAOYSA-N 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 4
- YYZUSRORWSJGET-UHFFFAOYSA-N ethyl octanoate Chemical compound CCCCCCCC(=O)OCC YYZUSRORWSJGET-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- CRSBERNSMYQZNG-UHFFFAOYSA-N 1 -dodecene Natural products CCCCCCCCCCC=C CRSBERNSMYQZNG-UHFFFAOYSA-N 0.000 description 3
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241000863430 Shewanella Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- LMGZGXSXHCMSAA-UHFFFAOYSA-N cyclodecane Chemical compound C1CCCCCCCCC1 LMGZGXSXHCMSAA-UHFFFAOYSA-N 0.000 description 3
- RGXWDWUGBIJHDO-UHFFFAOYSA-N decanoic acid ethyl ester Natural products CCCCCCCCCC(=O)OCC RGXWDWUGBIJHDO-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 3
- MMXKVMNBHPAILY-UHFFFAOYSA-N dodecanoic acid ethyl ester Natural products CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 3
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- AFFLGGQVNFXPEV-UHFFFAOYSA-N n-decene Natural products CCCCCCCCC=C AFFLGGQVNFXPEV-UHFFFAOYSA-N 0.000 description 3
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Chemical compound CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000002657 sphingoid group Chemical group 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- ZTEHOZMYMCEYRM-UHFFFAOYSA-N 1-chlorodecane Chemical compound CCCCCCCCCCCl ZTEHOZMYMCEYRM-UHFFFAOYSA-N 0.000 description 2
- CNDHHGUSRIZDSL-UHFFFAOYSA-N 1-chlorooctane Chemical compound CCCCCCCCCl CNDHHGUSRIZDSL-UHFFFAOYSA-N 0.000 description 2
- ADOBXTDBFNCOBN-UHFFFAOYSA-N 1-heptadecene Chemical compound CCCCCCCCCCCCCCCC=C ADOBXTDBFNCOBN-UHFFFAOYSA-N 0.000 description 2
- KWKAKUADMBZCLK-UHFFFAOYSA-N 1-octene Chemical compound CCCCCCC=C KWKAKUADMBZCLK-UHFFFAOYSA-N 0.000 description 2
- PJLHTVIBELQURV-UHFFFAOYSA-N 1-pentadecene Chemical compound CCCCCCCCCCCCCC=C PJLHTVIBELQURV-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 2-octanone Chemical compound CCCCCCC(C)=O ZPVFWPFBNIEHGJ-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- 241000187654 Nocardia Species 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical group ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940069096 dodecene Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- SHZIWNPUGXLXDT-UHFFFAOYSA-N ethyl hexanoate Chemical compound CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 229940093476 ethylene glycol Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- PFJKOHUKELZMLE-VEUXDRLPSA-N ganglioside GM3 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(=O)CCCCCCCCCCCCC\C=C/CCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 PFJKOHUKELZMLE-VEUXDRLPSA-N 0.000 description 2
- 150000002270 gangliosides Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- AOGQPLXWSUTHQB-UHFFFAOYSA-N hexyl acetate Chemical compound CCCCCCOC(C)=O AOGQPLXWSUTHQB-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YRHYCMZPEVDGFQ-UHFFFAOYSA-N methyl decanoate Chemical compound CCCCCCCCCC(=O)OC YRHYCMZPEVDGFQ-UHFFFAOYSA-N 0.000 description 2
- NUKZAGXMHTUAFE-UHFFFAOYSA-N methyl hexanoate Chemical compound CCCCCC(=O)OC NUKZAGXMHTUAFE-UHFFFAOYSA-N 0.000 description 2
- UQDUPQYQJKYHQI-UHFFFAOYSA-N methyl laurate Chemical compound CCCCCCCCCCCC(=O)OC UQDUPQYQJKYHQI-UHFFFAOYSA-N 0.000 description 2
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 2
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 2
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 2
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 150000003431 steroids Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- QMMJWQMCMRUYTG-UHFFFAOYSA-N 1,2,4,5-tetrachloro-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=C(Cl)C(Cl)=CC(Cl)=C1Cl QMMJWQMCMRUYTG-UHFFFAOYSA-N 0.000 description 1
- OCJBOOLMMGQPQU-UHFFFAOYSA-N 1,4-dichlorobenzene Chemical compound ClC1=CC=C(Cl)C=C1 OCJBOOLMMGQPQU-UHFFFAOYSA-N 0.000 description 1
- 239000005968 1-Decanol Substances 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N 1-ethenoxybutane Chemical compound CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- LIKMAJRDDDTEIG-UHFFFAOYSA-N 1-hexene Chemical compound CCCCC=C LIKMAJRDDDTEIG-UHFFFAOYSA-N 0.000 description 1
- ACYHSTUWOQNWCX-UHFFFAOYSA-N 2,2,3-trimethylheptane Chemical compound CCCCC(C)C(C)(C)C ACYHSTUWOQNWCX-UHFFFAOYSA-N 0.000 description 1
- IIYGOARYARWJBO-UHFFFAOYSA-N 2,2,4-trimethylheptane Chemical compound CCCC(C)CC(C)(C)C IIYGOARYARWJBO-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- LSKONYYRONEBKA-UHFFFAOYSA-N 2-Dodecanone Natural products CCCCCCCCCCC(C)=O LSKONYYRONEBKA-UHFFFAOYSA-N 0.000 description 1
- OKTWQKXBJUBAKS-WQADZSDSSA-N 2-[[(e,2r,3s)-2-amino-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC\C=C\[C@H](O)[C@H](N)COP(O)(=O)OCC[N+](C)(C)C OKTWQKXBJUBAKS-WQADZSDSSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWIQGIQRNBVZEN-UHFFFAOYSA-N 4-ethoxy-2-(2-ethoxy-2-oxoethyl)-2-hydroxy-4-oxobutanoic acid Chemical compound CCOC(=O)CC(O)(C(O)=O)CC(=O)OCC FWIQGIQRNBVZEN-UHFFFAOYSA-N 0.000 description 1
- KJYXVWHRKCNYKU-UHFFFAOYSA-M 4-ethylhexanoate Chemical compound CCC(CC)CCC([O-])=O KJYXVWHRKCNYKU-UHFFFAOYSA-M 0.000 description 1
- XZOYHFBNQHPJRQ-UHFFFAOYSA-M 7-methyloctanoate Chemical compound CC(C)CCCCCC([O-])=O XZOYHFBNQHPJRQ-UHFFFAOYSA-M 0.000 description 1
- OMIHGPLIXGGMJB-UHFFFAOYSA-N 7-oxabicyclo[4.1.0]hepta-1,3,5-triene Chemical compound C1=CC=C2OC2=C1 OMIHGPLIXGGMJB-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NHTMVDHEPJAVLT-UHFFFAOYSA-N Isooctane Chemical compound CC(C)CC(C)(C)C NHTMVDHEPJAVLT-UHFFFAOYSA-N 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000005640 Methyl decanoate Substances 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Natural products P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 241001518135 Shewanella algae Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- ULBTUVJTXULMLP-UHFFFAOYSA-N butyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCC ULBTUVJTXULMLP-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- WFRBMXFCEAHLGH-UHFFFAOYSA-N cyclodecanol Chemical compound OC1CCCCCCCCC1 WFRBMXFCEAHLGH-UHFFFAOYSA-N 0.000 description 1
- UCIYGNATMHQYCT-OWOJBTEDSA-N cyclodecene Chemical compound C1CCCC\C=C\CCC1 UCIYGNATMHQYCT-OWOJBTEDSA-N 0.000 description 1
- 229930007927 cymene Natural products 0.000 description 1
- JDPQWHLMBJZURR-UHFFFAOYSA-N decan-5-one Chemical compound CCCCCC(=O)CCCC JDPQWHLMBJZURR-UHFFFAOYSA-N 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 229940117389 dichlorobenzene Drugs 0.000 description 1
- CMMUKUYEPRGBFB-UHFFFAOYSA-L dichromic acid Chemical compound O[Cr](=O)(=O)O[Cr](O)(=O)=O CMMUKUYEPRGBFB-UHFFFAOYSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- JVSWJIKNEAIKJW-UHFFFAOYSA-N dimethyl-hexane Natural products CCCCCC(C)C JVSWJIKNEAIKJW-UHFFFAOYSA-N 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 1
- GIVLTTJNORAZON-HDBOBKCLSA-N ganglioside GM2 (18:0) Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 GIVLTTJNORAZON-HDBOBKCLSA-N 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 239000007986 glycine-NaOH buffer Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- IMFQJEYLZQBUBU-UHFFFAOYSA-N hexane;octane Chemical compound CCCCCC.CCCCCCCC IMFQJEYLZQBUBU-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 238000006698 hydrazinolysis reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- ZAJNGDIORYACQU-UHFFFAOYSA-N methyl n-octyl ketone Natural products CCCCCCCCC(C)=O ZAJNGDIORYACQU-UHFFFAOYSA-N 0.000 description 1
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 125000004149 thio group Chemical group *S* 0.000 description 1
- UBOXGVDOUJQMTN-UHFFFAOYSA-N trichloroethylene Natural products ClCC(Cl)Cl UBOXGVDOUJQMTN-UHFFFAOYSA-N 0.000 description 1
- 241001446247 uncultured actinomycete Species 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/001—Amines; Imines
Definitions
- the present invention relates to a method for producing lysosphingolipids, and more specifically, a method for industrially useful production of lysosphingolipids useful for cosmetics, medicines, sphingolipid engineering, cell engineering, etc., and lysosphingolipids obtained by the production method.
- Conventional technology a method for producing lysosphingolipids, and more specifically, a method for industrially useful production of lysosphingolipids useful for cosmetics, medicines, sphingolipid engineering, cell engineering, etc., and lysosphingolipids obtained by the production method.
- the sphingo lipid is a generic name of lipids having a sphingoid skeleton as a common structure, such as sphingo glycolipid, sphingo phospholipid (including sphingophosphonolipid), and ceramide.
- the amino group of the sphingoid skeleton forms a ceramide by acid amide bonding of a long-chain fatty acid having a non-uniform chain length.
- these sphingolipids have been widely distributed from lower animals to higher animals, and it has been revealed that they are playing important roles in biological activities such as cell proliferation, differentiation induction, apoptosis, etc. is there. Since it is a component of the cell surface, it is also being used as an additive to cosmetics, pharmaceuticals, etc.
- lyso-sphingolipid N-defasylated form of sphingolipids (lyso-form), which lacks a fatty acid bonded to the amide group of the sphingolipid sphingoid by an acid amide, is called lyso-sphingolipid and differs from sphingolipids in biological activity as well as sphingolipids. It has been shown that it also has activity.
- the lysosphingolipid has a free amino group in the sphingoid and is useful as a starting material when synthesizing a lysosphingolipid derivative (a sphingolipid derivative or a sphingolipid analog) by re-ascination.
- a lysosphingolipid derivative a sphingolipid derivative or a sphingolipid analog
- sphingolipids labeled with a chromophore / radioisotope can be obtained.
- free amino acids of lysosphingolipids It is also possible to immobilize the compound on a carrier using a thio group.
- lysosphingolipids As chemical methods for obtaining lysosphingolipids from glycosphingolipids, hydrazinolysis and alkali hydrolysis in alcoholic solvents are known. However, according to these methods, for example, in the case of glycosphingolipids containing sialic acid (ganglioside), the desialylation reaction of the sialic acid portion proceeds simultaneously. In addition, in the case of glycosphingolipids containing amino sugars, elimination of the N-acetyl group occurs, resulting in de-N-acetyl lysoglycolipids.
- a protecting group was selectively introduced into the amino group of the lipid moiety, and then the sialic acid moiety was re-acylated. After that, very complicated operations such as a method of further removing the protecting group and a method of incorporation into a liposome to selectively resuylate the sugar were required. In addition, these operations produce various by-products. Thus, the production of lysosphingolipids by a chemical method requires a lot of labor and technical skill.
- sphingoides are not only of the natural D-erythro (2S, 3R) type, but also of the L-threo (L-threo) type (2S, Since various side-reactions occur, such as the generation of 3S) stereoisomer, not only the yield of the target natural D-erythro form is low, but also the Was very difficult to purify.
- the reaction yield of the lyso form in the method using these enzymes is not satisfactory.
- the maximum hydrolyzable substrate, ganglioside GM2 is about 70, depending on the substrate. /. And up to about 60% for ganglioside GM1.
- JP-A Japanese Patent Application Laid-Open No. 7-107988
- a bacterium belonging to the genus Pseudomonas or Shewanella that produces sphingolipid ceramide N-deacylase.
- Japanese Patent Application Laid-Open No. H10-45 Japanese Patent Application Laid-Open No. H10-45
- the method of adding to the culture medium requires a large amount of impurities such as pigments and glycolipids derived from the culture medium or cells in addition to the target lyso form. A complicated purification operation was required. Furthermore, in this method, it was very difficult to treat a trace amount of sphingolipids and to purify the lyso form for the reasons described above.
- an object of the present invention is to provide a method for efficiently producing lysosphingolipids without producing by-products.
- Another object of the present invention is to provide a lysosphingolipid obtained by the above production method.
- FIG. 1 is a graph showing an optimal pH that contributes to the yield of a lyso form in the presence of an organic solvent.
- FIG. 2 is a view showing substrate specificity that contributes to the yield of a lyso form in the presence and absence of an organic solvent.
- FIG. 3 is a graph showing the time course of the yield of the lyso form in the presence or absence of a surfactant and an organic solvent.
- FIG. 4 is a graph showing the yield of lyso-form at various enzyme amounts in the presence of an organic solvent.
- FIG. 5 is a diagram showing the relationship between the amount of the organic solvent added and the yield of the lyso form.
- the present inventors have studied a method for preparing a large amount of high-purity industrially advantageous lysosphingolipids, and as a result, have found that an enzyme that specifically hydrolyzes the acid amide bond between a sphingoid of a sphingolipid and a fatty acid is obtained.
- the enzymatic reaction is carried out in a two-phase reaction solution containing an organic solvent immiscible with water, so that by-products do not occur and excellent reaction efficiency is achieved. It has been found that high-purity lysophosphingolipids can be produced.
- a method for producing lysosphingolipids using an enzyme that specifically hydrolyzes an acid amide bond between a sphingoid and a fatty acid of a sphingolipid comprising at least one organic solvent that forms a separated phase with an aqueous phase.
- a method for producing lysosphingolipids comprising performing an enzyme reaction in a two-phase reaction solution,
- ether is an ether selected from the group consisting of phenylene ether, ethyleneglycol monolecithinolene ether, disopropyl ether and vinylethyl ether.
- the surfactant is selected from the group consisting of a surfactant having a steroid skeleton, polyoxyethylene alkylphenyl ether, polyoxyethylene sorbitan alkyl ether and boroxixylene alkyl ether.
- Rhizosph ingolipid obtained by the production method according to any one of the above 1 to 8
- ⁇ ⁇ means a trade name
- examples of the sphingolipid used as a substrate include a simple substance of a natural or synthetic substance having a long-chain base sphingoid including glycosphingolipid, sphingolipid, and ceramide, and a mixture thereof.
- lysosphingolipid means a ⁇ -desacyl derivative of a sphingolipid lacking a fatty acid having an acid amide bond to an amino group of sphingoid.
- the enzyme used in the present invention that specifically hydrolyzes the acid amide bond between the sphingolipid sphingolipid and the fatty acid is not particularly limited, and may be a known enzyme capable of releasing fatty acid from sphingolipid.
- ganglioside ceramidase produced by actinomycetes of the genus Nocardia [Journal of Bio-Chemistry, Vol. 103, pp.
- JP-A-8-84587 sphingolipid ceramide ⁇ -deacylase produced by a bacterium of the genus Schwanella (JP-A-10-45792), a bacterium belonging to the genus Shudoumonas Ceramidase (Japanese Unexamined Patent Publication No. H10-145563), a ceramidase derived from mammals and seori [Journal 'ob' 'Biological' chemistry, Vol. 241, pp. 3731-3737 (1966 ); Biochemistry, Vol. 8, pp. 1692-1698 (1969); Biochemical force
- sufingolipid ceramide N produced by Pseudomonas sp.
- Desylases and the sphingolipid ceramide N-deacylase produced by the bacteria of the genus Shewanella have wide substrate specificity and are particularly preferred for producing various lysosphingolipids:
- a genus of Pseudomonas sp. TK_4, which produces a sphingolipid ceramide N-deacylase, is designated as G-182, and is designated as G-182.
- These enzymes can be used as an enzyme solution or immobilized on a water-insoluble carrier.
- the aqueous phase used in the present invention includes water or an aqueous solution, and in particular, a buffer containing an enzyme, a substrate, and the like for various reactions is preferable.
- the separated phase is an organic solvent phase that is immiscible with water.
- the distribution ratio of fatty acids, which are decomposition products of sphingolipids, to the organic solvent phase is higher than that of the aqueous phase, and the distribution ratio of sphingolipids, a substrate, to the organic solvent is higher.
- organic solvent examples include, but are not limited to, hexane, heptane, octane, isooctane, nonane, decane, dodecane, pentadecane, heptadecane, octadecane, 2-methylbentan, and 2,2 as hydrocarbons.
- alcohols examples include octanol, decanol, dodecanol, otatenol, decenol, cyclodecanol, and the like.
- esters examples include ethyl hexanoate, ethyl octanoate, ethyl ethyl decanoate, ethyl ethyl dodecanoate, isopropyl myristate, butyl stearate, butyl citrate, and ethyl ethyl citrate.
- ethers examples include phenyl ether, vinylethynole ether, ethylene glycol getyl ether, diisopropyl ether tenol, and octyl ether.
- Ketones include octanone, decanone, dodecanone and the like.
- hydrocarbons with 6 or more carbon atoms including aliphatic, cyclic, aromatic, and halogen-containing hydrocarbons
- alcohols with 8 or more carbon atoms and carboxylic acid portions with 6 or more carbon atoms
- an ester selected from alcohols having 2 or more carbon atoms, and ethers selected from phenyl ether, ethylene glycol dimethyl ether, diisopropyl ether and vinyl ethyl ester are particularly preferably used in the method of the present invention. Can be used.
- organic solvent used in the present invention is not limited to one kind, and two or more kinds can be mixed and used.
- the two-phase system in the present invention includes an aqueous phase and an organic solvent phase, for example, a state in which an aqueous phase is dispersed in an organic solvent phase, such as a stirring state, or a state in which an organic solvent phase is dispersed in an aqueous phase.
- ⁇ means a state in which an aqueous phase and an organic solvent phase are in contact with each other in a state of being separated into two layers, not in a dispersed state as in a stationary state.
- the organic solvent phase and / or the aqueous phase may be exchanged as needed while continuing the enzymatic reaction, thereby making it possible to continuously produce lysosphingolipids.
- the amount of the organic solvent to be added is not particularly limited, but is preferably 50% or more of the volume of the aqueous phase, usually 5 to 10 times the volume.
- the aqueous phase contains various salts and surfactants, for example, surfactants having a steroid skeleton such as sodium taurodeoxycholate and sodium cholate, triton surfactants, and nonidet P-40 '" Holoxyethylene alkylphenyl acrylate
- non-ionic surfactants such as polyoxyethylene sorbitan alkyl ethers such as ters, tween-based surfactants, and borooxyethylene alkyl ethers can be added.
- the amount of the surfactant is usually preferably about 0.1 to 2% by weight based on the whole reaction system.
- the reaction conditions are not particularly limited, it is possible to produce lysosphingolipids more efficiently by carrying out the reaction under the optimum conditions of each enzyme such as pH and temperature.
- the pH is 6 to 10
- a surfactant such as sodium taurodeoxycholate or sodium cholate is used as a surfactant. It is preferable to add a surfactant having a skeleton of phosphine, and to use sphingo more efficiently by using a boroxyethylene alkylphenyl ether such as Triton X-100 TM or Nonidet P-40 TM in combination. Lipids can be hydrolyzed.
- the reaction time is also not particularly limited, and a desired amount of lysosphingolipid can be obtained with the enzyme used from the substrate used, for example, a natural or synthetic glycosphingolipid, a sphingophospholipid such as a sphingophospholipid, or a ceramide. You just have to react for time.
- the lysosphingolipid obtained according to the present invention can be purified by a usual method.
- the two phases may be separated by standing and then separated, or a selective membrane or column may be used. It may be removed by concentration under reduced pressure or distillation. Since the reaction product containing the lyso-form in the aqueous phase obtained in this way has a small amount of contaminants, it is subjected to a usual extraction method, for example, reverse-phase chromatography, normal-phase gel chromatography using a silica gel, or The lysos-fingolipid can be easily purified by ion-exchange chromatography.
- the lysosphingolipid derivative obtained by the present invention can be treated to produce a lysosphingolipid derivative.
- the lysosphingolipid derivative can be produced, for example, as follows.
- the re-acylation can be performed by a chemical method or an enzymatic method according to a conventional method of acid amidation of an amino group.
- the reaction may be carried out using aliphatic carboxylic acid with or without a label or a reactive derivative thereof.
- aliphatic carboxylic acids that can be used in the present invention include saturated fatty acids and unsaturated fatty acids, as well as those in which the hydrocarbon chain of the fatty acid is a halogen, a substituted or unsubstituted amino group, an oxo group, a hydroxyl group.
- all aliphatic carboxylic acids such as acids having oxygen, sulfur and amino groups in the hydrocarbon chain.
- a method for enzymatic reacylation there is a method using a known lipase.
- a particularly useful method is to specifically hydrolyze an acid amide bond between a sphingoid of a sphingolipid and a fatty acid. It can be easily carried out by utilizing the reverse reaction of an enzyme, for example, the above-mentioned sphingolipid ceramide N-deacylase (International Publication W098 / 035929).
- the labeling method is to introduce a chromophore-forming substance, a fluorescent substance, biotin, a radioisotope, etc. into the labeling portion. good.
- GM1 [Matoreya (Matreya) Co.] 50 mM acetate buffer containing (pH6. 0) to 1 0 mu 1, by adding various organic solvents 1 00 mu i, at 37 ° C, c which was reacted for 1 6 hr As a control, a reaction solution without the addition of an organic solvent was similarly reacted.c. The resulting reaction solution was developed by thin-layer chromatography, developed with orcinol sulfuric acid, and then developed with an imaging densitometer. GM1 (manufactured by Bio-Rad)]. The results are shown in Table 1.
- the resulting reaction solution was developed by thin-layer chromatography, colored with orcinol sulfate, and the lyso form of GM1 was analyzed with an imaging densitometer (Bio-Rad) as in Example 1. The yield was quantified. The results are shown in Table 2. The final concentration of the surfactant was 0.8% by weight based on the reaction system. Among the surfactants listed in Table 2 below, Triton X-100 IM was manufactured by Pierce and all others were used. Made by Nacalai Tesque
- the resulting reaction solution was developed by thin-layer chromatography and colored with orcinol sulfate as in Example 1, and the GM1 lyso form was collected with an imaging densitometer (Bio-Rad). The rate was determined.
- the results are shown in Table 3: The concentration of the surfactant in Table 3 is the weight of the final concentration relative to the reaction system. It is.
- the obtained reaction solution was developed by thin-layer chromatography and colored with honoresinol sulfate as in Example 1, and then the GM1 decomposition rate was determined by an imaging densitometer (manufactured by Bio-Rad). The lyso-form yield was quantified.
- Figure 1 shows the results.
- FIG. 1 is a graph showing the optimum pH that contributes to the yield of the lyso form in the presence of an organic solvent.
- the vertical axis indicates the degradation rate (%) and the horizontal axis indicates the pH.
- White circles indicate acetate buffer
- black circles indicate phosphate buffer
- white triangles indicate Tris-HCl buffer
- black squares indicate glycine NaOH buffer. Show liquid.
- the reaction was performed at 7 ° C for 16 hours. Controls without the addition of n-heptadecane were also prepared: substrates were ceramide (Cer), galactosylceramide (GalCer), sulfatide, G ⁇ 1, asia mouth GM1, GDla, sphingo myelin (all matreya) It was used.
- substrates were ceramide (Cer), galactosylceramide (GalCer), sulfatide, G ⁇ 1, asia mouth GM1, GDla, sphingo myelin (all matreya) It was used.
- the yield of the lyso form of ceramide was determined by thin-layer chromatography, and the color of sphingosine produced by the ninhydrin reagent was developed.
- sphingomyelin the color of lysosphingomyelin produced by Coomassie brilliant blue was developed.
- the other substrates were developed by thin-layer chromatography, developed with orcinol sulfuric acid, and then imaged with an imaging densitometer (Bio-Rad), as in Example 1. The yield of the lyso form was quantified. Figure 2 shows the results.
- FIG. 2 is a diagram showing substrate specificity that contributes to the yield of the lyso form in the presence and absence of an organic solvent.
- the vertical axis shows the yield (%)
- the horizontal axis shows each substrate
- the black bar graph shows the decomposition rate in the presence of n-heptadecane
- the white bar graph shows the decomposition rate in the absence of n-heptadecane. Show.
- reaction was carried out at 37 ° C under the following reaction conditions (A) to (D), and 0.5, 0.5, 1, 2,
- the yield was quantified every 6 and 16 hours.
- the resulting reaction solution was developed by thin-layer chromatography and color-developed with orcinol sulfuric acid in the same manner as in Example 1, followed by imaging densitometer (Bio-Rad, the rate of GM 1 decomposition, That is, the yield of the lyso form was quantified, and the results are shown in FIG.
- Figure 3 shows that GM in the presence or absence of a surfactant and an organic solvent
- FIG. 4 is a diagram showing the time course of the decomposition rate of FIG.
- the vertical axis shows the decomposition rate (%)
- the horizontal axis shows the time (hr)
- the black circles indicate the presence of sodium taurodeoxycholate and n-decane
- the white circles indicate the presence of sodium taurodeoxycholate
- the black squares indicates the presence of Triton X- 100 ⁇ and n-decane
- the open triangle indicates the presence of Triton X-100 TM.
- the resulting reaction solution was developed by thin-layer chromatography and colored with orcinol sulfuric acid in the same manner as in Example 1. After that, the decomposition rate of GM1 was determined by an imaging densitometer (manufactured by Bio-Rad). Then, the yield of the lyso form was quantified: FIG. 4 shows the results.
- FIG. 4 is a graph showing the degradation rates of GM1 with various amounts of enzymes in the presence of sodium taurodeoxycholate, various types of Triton ⁇ - 100 ⁇ ′, and an organic solvent.
- the vertical axis shows the degradation rate (%) and the horizontal axis shows the concentration (%) of Triton X-100 TM. .
- the resulting reaction solution was developed by thin-layer chromatography and colored with orcinol sulfuric acid in the same manner as in Example 1. After that, the decomposition rate of GM1 was determined by an imaging densitometer (manufactured by Bio-Rad). The lyso-form yield was quantified. Figure 5 shows the results.
- FIG. 5 is a diagram showing the relationship between the amount of the organic solvent and the yield of the lyso form.
- the vertical axis shows the decomposition rate (%)
- the horizontal axis shows the amount of organic solvent ( ⁇ 1)
- the white bar graph shows ⁇ -decane
- the black bar graph shows ⁇ -heptadecane.
- the obtained reaction solution was developed by thin-layer chromatography and color-developed with orcinol sulfate as in Example 1, and then the lyso form of GM1 was analyzed with an imaging densitometer (Bio-Rad). The yield was quantified. Table 5 shows the results. The final concentration of the mixed surfactant is 0.1 weight based on the reaction system. /. Used in: Among the surfactants listed in Table 5 below, Triton X-100 TM is manufactured by Pierce, and all others are Nacalai Tester tt.
- ganglioside GM3 Dissolve 10 mg of ganglioside GM3 (manufactured by Matreya) in 10 ml of 0.5 OmM acetate buffer (pH 6.0) containing 0.8% sodium taurodeoxycholate and place in a 20 Om1 pear-shaped flask. S CDase2 U was added. Here, 100 ml of n-decane was overlaid and allowed to stand still at 37 ° C. for 16 hours. 1 U of SCDase was added to the aqueous phase, and the mixture was kept at 37 ° C for another 16 hours. At this time, the decomposition rate of ganglioside GM3 was 95%.
- aqueous phase was recovered and divided into two equal parts, which were subjected to purification by reverse phase chromatography.
- the eluted lysoganglioside GM 3 fractions were collected, concentrated and dried. As a result, 5.6 mg of a lyso-form having a purity of 95% or more was obtained by color development using a mixed solution of orcinol sulfuric acid and dichromic acid / sulfuric acid after development by thin layer chromatography.
- the production method of the present invention makes it possible to industrially mass-produce high-purity lysosphingolipids efficiently and simply.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99910758A EP1067196B1 (en) | 1998-03-31 | 1999-03-30 | Process for producing lysosphingolipids |
DE69940426T DE69940426D1 (de) | 1998-03-31 | 1999-03-30 | Verfahren zur herstellung von lysosphingolipiden |
JP2000541321A JP4331896B2 (ja) | 1998-03-31 | 1999-03-30 | リゾスフィンゴ脂質の製造方法 |
AU29597/99A AU745467B2 (en) | 1998-03-31 | 1999-03-30 | Process for producing lysosphingolipids |
US09/647,135 US7045322B1 (en) | 1998-03-31 | 1999-03-30 | Process for producing lysosphingolipids |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP10174598 | 1998-03-31 | ||
JP10/101745 | 1998-03-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999050433A1 true WO1999050433A1 (fr) | 1999-10-07 |
Family
ID=14308794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/001610 WO1999050433A1 (fr) | 1998-03-31 | 1999-03-30 | Methode de production de lysosphingolipides |
Country Status (9)
Country | Link |
---|---|
US (1) | US7045322B1 (ja) |
EP (1) | EP1067196B1 (ja) |
JP (1) | JP4331896B2 (ja) |
KR (1) | KR100585471B1 (ja) |
CN (1) | CN1131317C (ja) |
AT (1) | ATE423215T1 (ja) |
AU (1) | AU745467B2 (ja) |
DE (1) | DE69940426D1 (ja) |
WO (1) | WO1999050433A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2241330A1 (en) | 2003-02-14 | 2010-10-20 | The Curators Of The University Of Missouri | Contraceptive methods and compositions related to proteasomal interference |
WO2011138776A2 (en) | 2010-05-06 | 2011-11-10 | Hervana Ltd. | Biologic female contraceptives |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103884782B (zh) * | 2012-12-21 | 2015-12-02 | 中国科学院大连化学物理研究所 | 基于液相色谱-质谱联用的大规模血浆鞘脂轮廓分析方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0670789A (ja) * | 1992-08-28 | 1994-03-15 | Fuji Oil Co Ltd | グリセロ糖脂質の製造法 |
JPH09173092A (ja) * | 1995-12-08 | 1997-07-08 | Italfarmaco Sud Spa | ホスファチジルセリンの工業的製造方法 |
WO1998003529A1 (fr) | 1996-07-19 | 1998-01-29 | Takara Shuzo Co., Ltd. | Procede de preparation de sphingolipides et de derives de sphingolipides |
JPH1045792A (ja) * | 1996-07-26 | 1998-02-17 | Takara Shuzo Co Ltd | リゾスフィンゴ脂質の製造方法 |
JPH10257884A (ja) * | 1997-03-18 | 1998-09-29 | Takara Shuzo Co Ltd | スフィンゴ脂質セラミドn−デアシラーゼ |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT978495B (it) * | 1973-01-26 | 1974-09-20 | Antonimi E | Procedimento per condurre reazio ni enzimatiche mediante l uso di sistemi bifasici acquoso organici |
JPH0798708B2 (ja) * | 1987-08-13 | 1995-10-25 | 電気化学工業株式会社 | 熱分解窒化ホウ素被覆物品の製造方法 |
US5143841A (en) | 1987-08-28 | 1992-09-01 | Toyo Jozo Company, Ltd. | Ganglioside ceramidase and process for producing same |
JPS6460379A (en) | 1987-08-28 | 1989-03-07 | Toyo Jozo Kk | Novel ganglioside ceramidase and production thereof |
US5108916A (en) * | 1989-06-05 | 1992-04-28 | Rhone-Poulenc Rorer, S.A. | Process for stereoselectively hydrolyzing, transesterifying or esterifying with immobilized isozyme of lipase from candida rugosa |
EP0547655A1 (en) | 1991-12-11 | 1993-06-23 | Duphar International Research B.V | Method of preparing optically active cyanohydrins |
JP3035602B2 (ja) | 1992-09-04 | 2000-04-24 | 工業技術院長 | リゾスフィンゴ糖脂質の製造法及びこれに用いる新規ロドコッカス属微生物 |
AU6843494A (en) * | 1993-05-06 | 1994-12-12 | Gist-Brocades N.V. | Enzymatic synthesis of ceramides and hybrid ceramides |
JPH07107988A (ja) | 1993-10-13 | 1995-04-25 | Higashimaru Shoyu Kk | リゾ糖脂質の製造方法 |
EP0707063B1 (en) * | 1994-07-21 | 1998-06-17 | Takara Shuzo Co. Ltd. | Glycolipid ceramide deacylase |
JP3669595B2 (ja) * | 1994-07-21 | 2005-07-06 | タカラバイオ株式会社 | スフィンゴ脂質セラミドデアシラーゼ |
JP3729468B2 (ja) | 1996-07-05 | 2005-12-21 | タカラバイオ株式会社 | シュードモナス属に属するセラミダーゼ生産菌 |
-
1999
- 1999-03-30 AT AT99910758T patent/ATE423215T1/de not_active IP Right Cessation
- 1999-03-30 AU AU29597/99A patent/AU745467B2/en not_active Ceased
- 1999-03-30 WO PCT/JP1999/001610 patent/WO1999050433A1/ja not_active Application Discontinuation
- 1999-03-30 EP EP99910758A patent/EP1067196B1/en not_active Expired - Lifetime
- 1999-03-30 KR KR1020007010210A patent/KR100585471B1/ko not_active IP Right Cessation
- 1999-03-30 CN CN99804807A patent/CN1131317C/zh not_active Expired - Fee Related
- 1999-03-30 JP JP2000541321A patent/JP4331896B2/ja not_active Expired - Fee Related
- 1999-03-30 US US09/647,135 patent/US7045322B1/en not_active Expired - Fee Related
- 1999-03-30 DE DE69940426T patent/DE69940426D1/de not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0670789A (ja) * | 1992-08-28 | 1994-03-15 | Fuji Oil Co Ltd | グリセロ糖脂質の製造法 |
JPH09173092A (ja) * | 1995-12-08 | 1997-07-08 | Italfarmaco Sud Spa | ホスファチジルセリンの工業的製造方法 |
WO1998003529A1 (fr) | 1996-07-19 | 1998-01-29 | Takara Shuzo Co., Ltd. | Procede de preparation de sphingolipides et de derives de sphingolipides |
JPH1045792A (ja) * | 1996-07-26 | 1998-02-17 | Takara Shuzo Co Ltd | リゾスフィンゴ脂質の製造方法 |
JPH10257884A (ja) * | 1997-03-18 | 1998-09-29 | Takara Shuzo Co Ltd | スフィンゴ脂質セラミドn−デアシラーゼ |
Non-Patent Citations (1)
Title |
---|
See also references of EP1067196A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2241330A1 (en) | 2003-02-14 | 2010-10-20 | The Curators Of The University Of Missouri | Contraceptive methods and compositions related to proteasomal interference |
WO2011138776A2 (en) | 2010-05-06 | 2011-11-10 | Hervana Ltd. | Biologic female contraceptives |
Also Published As
Publication number | Publication date |
---|---|
CN1131317C (zh) | 2003-12-17 |
ATE423215T1 (de) | 2009-03-15 |
EP1067196B1 (en) | 2009-02-18 |
EP1067196A1 (en) | 2001-01-10 |
CN1296528A (zh) | 2001-05-23 |
US7045322B1 (en) | 2006-05-16 |
EP1067196A4 (en) | 2004-09-22 |
KR20010041906A (ko) | 2001-05-25 |
DE69940426D1 (de) | 2009-04-02 |
KR100585471B1 (ko) | 2006-06-02 |
AU745467B2 (en) | 2002-03-21 |
JP4331896B2 (ja) | 2009-09-16 |
AU2959799A (en) | 1999-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPS59187792A (ja) | 酵素法リン脂質糖類誘導体の製法 | |
JP3734198B2 (ja) | スフィンゴ脂質及びスフィンゴ脂質誘導体の製造方法 | |
Nakajima et al. | A facile transphosphatidylation reaction using a culture supernatant of actinomycetes directly as a phospholipase D catalyst with a chelating agent | |
WO1999050433A1 (fr) | Methode de production de lysosphingolipides | |
US5100787A (en) | Method for preparing highly purified phosphatidylinositol | |
JP3625244B2 (ja) | リゾスフィンゴ脂質の製造方法 | |
JP3813980B2 (ja) | リゾスフィンゴ脂質の製造方法 | |
US6428999B1 (en) | Sphingolipid ceramide N-deacylase, methods for producing sphingolipids and sphingolipid derivatives, and spingolipid ceramide N-deacylase gene | |
JP3868052B2 (ja) | スフィンゴ脂質セラミドn−デアシラーゼ | |
JPH0884587A (ja) | 糖脂質セラミドデアシラーゼ | |
JP2010200690A (ja) | 新規スフィンゴ脂質及びその製造方法 | |
JP2683590B2 (ja) | 酵素変換リン脂質の製造法 | |
JP2832746B2 (ja) | スフィンゴ糖脂質の製造方法 | |
Makula et al. | Identification and synthesis of acyl-phosphatidylglycerol in Acinetobacter sp. HO1-N | |
KR100225669B1 (ko) | 효소를 이용한 고순도 인지질의 생산방법 | |
Furuyoshi et al. | Acyl group transfer from the sn-1 position of phospholipids in the biosynthesis of n-dodecyl palmitate | |
Rosenberg | Sphingomyelin: enzymatic reactions | |
JPH075615B2 (ja) | リン脂質誘導体 | |
WO2007102396A1 (ja) | 標識スフィンゴ脂質の製造方法 | |
JPH0471497A (ja) | モノアシルグリセロリン脂質の製造方法 | |
Satoa et al. | Asymmetric in vitro Synthesis of Diastereomeric Phosphatidylglycerols from Phosphatidylcholine and Glycerol by Bacterial Phospholipase D | |
JPH11276191A (ja) | スフィンゴ糖脂質の製造法 | |
JPH10248558A (ja) | 超臨界流体中での酵素反応方法 | |
JPH04360690A (ja) | ジアシルグリセロリン脂質の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99804807.0 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR MX US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 29597/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007010210 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999910758 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09647135 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999910758 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007010210 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 29597/99 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007010210 Country of ref document: KR |